Haematology
KRT-232-115
KRT-232-115: A Front-Line, Phase 3, Randomized, Double-Blind, Add-On Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Myelofibrosis Patients Who Have a Suboptimal Response to Ruxolitinib
Trial overview
Disease
Haematology
Topic
Myleofibrosis
Sponsor
Kartos Therapeutics
Description
KRT-232-115: A Front-Line, Phase 3, Randomized, Double-Blind, Add-On Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Myelofibrosis Patients Who Have a Suboptimal Response to Ruxolitinib
Study details
details to follow
Trial status
Due to open May 24 in Oxford and Windsor
Location
Priniciple Investigator
Dr Bethan Psalia - Oxford
Dr Pratap Neelakatan - Windsor